Systematic review and meta-analysis assess late-stage outcomes as predictors of cancer mortality, suggesting potential forecasting utility.
Figure S4 shows the Evaluation of the utility of regarding the 95% CI RR for late-stage incidence as a “forecast” of the final trial result for cancer-specific mortality, only including 15 trial arm comparisons with the late-stage outcome RR reported prior to the primary analysis for mortality but after the screening period had ended.
No takes yet. Share an insight, caveat, or question.
Rebolj et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: